Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Terminated Phase 2 Trials for Sorafenib (DB00398)

Also known as: Transitional cell cancer of the renal pelvis and ureter recurrent / Renal pelvis and ureter transitional cell cancer recurrent / Renal pelvis and ureteric cancer recurrent transitional cell / Renal pelvis and ureteral cancer transitional cell recurrent / Renal pelvis and ureteric cancer transitional cell recurrent

IndicationStatusPhase
DBCOND0028816 (Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00112905Sorafenib in Treating Patients With Regional or Metastatic Cancer of the UrotheliumTreatment